Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline P Ernest

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Annual Review of Pharmacology and Toxicology|August 19, 2020
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant TuberculosisJacqueline P Ernest, Natasha Strydom, Qianwen Wang, et al.
International Journal of Antimicrobial Agents|June 20, 2022
Pharmacometrics in tuberculosis: progress and opportunitiesJustin J Wilkins, Elin M Svensson, Jacqueline P Ernest, et al.
Clinical Pharmacology and Therapeutics|April 15, 2020
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug RepurposingMaria Garcia-Cremades, Belen P Solans, Emma Hughes, et al.
Science Translational Medicine|February 5, 2025
Selection and prioritization of candidate combination regimens for the treatment of tuberculosisNatasha Strydom, Rob C van Wijk, Qianwen Wang, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2021
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling StudyKendra K Radtke, Jacqueline P Ernest, Nan Zhang, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugsJacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, et al.
The European Respiratory Journal|June 15, 2023
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugsJacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, et al.
The Journal of Infectious Diseases|February 17, 2025
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine ModelsBernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary TuberculosisJacqueline P Ernest, Jansy Sarathy, Ning Wang, et al.
The Journal of Infectious Diseases|June 4, 2025
The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of ResistanceAnnamarie E Bustion, Jacqueline P Ernest, Firat Kaya, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Annual Review of Pharmacology and Toxicology|August 19, 2020
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant TuberculosisJacqueline P Ernest, Natasha Strydom, Qianwen Wang, et al.
International Journal of Antimicrobial Agents|June 20, 2022
Pharmacometrics in tuberculosis: progress and opportunitiesJustin J Wilkins, Elin M Svensson, Jacqueline P Ernest, et al.
Clinical Pharmacology and Therapeutics|April 15, 2020
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug RepurposingMaria Garcia-Cremades, Belen P Solans, Emma Hughes, et al.
Science Translational Medicine|February 5, 2025
Selection and prioritization of candidate combination regimens for the treatment of tuberculosisNatasha Strydom, Rob C van Wijk, Qianwen Wang, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2021
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling StudyKendra K Radtke, Jacqueline P Ernest, Nan Zhang, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugsJacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, et al.
The European Respiratory Journal|June 15, 2023
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugsJacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, et al.
The Journal of Infectious Diseases|February 17, 2025
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine ModelsBernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary TuberculosisJacqueline P Ernest, Jansy Sarathy, Ning Wang, et al.
The Journal of Infectious Diseases|June 4, 2025
The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of ResistanceAnnamarie E Bustion, Jacqueline P Ernest, Firat Kaya, et al.
Pageof 2